Patents by Inventor Mark E. Cartwright

Mark E. Cartwright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PATHOGEN VACCINES AND METHODS OF PRODUCING AND USING THE SAME
    Publication number: 20240108709
    Abstract: The present invention provides vaccine compositions and methods of producing such compositions. Other embodiments of the invention include methods of treating a pathogen infection, methods of vaccinating a subject against a pathogen infection, and methods for treating an antibiotic-resistance bacterial infection in a subject in need thereof. In further embodiments, the invention includes methods of decreasing the level of a pathogen in a subject having a pathogen infection, methods of increasing the surviving rate of a subject having a pathogen infection, methods of reducing the level of pain associated with a pathogen infection, and methods of reducing the level of distress associated with a pathogen infection in a subject in need thereof. Novel scaffold compositions and opsonin-bound or lectin-bound pathogen compositions, and uses thereof, are also provided herein.
    Type: Application
    Filed: March 20, 2023
    Publication date: April 4, 2024
    Applicant: President and Fellows of Harvard College
    Inventors: Michael Super, Edward J. Doherty, Mark Joseph Cartwright, Des White, Alexander Stafford, Omar Abdel-Rahman Ali, Amanda Graveline, Donald E. Ingber, David J. Mooney, Benjamin Seiler
  • Use of neurokinin receptor antagonists to treat androgen-dependent diseases
    Patent number: 6569872
    Abstract: Use of an antagonist selected from the group consisting of: (a) antagonists of neurokinin-1 (NK1), neurokinin-2 (NK2) and neurokinin-3 (NK3) receptors, (b) antagonists of NK1 and NK2 receptors, (c) antagonists of NK2 and NK3 receptors, (d) antagonists of NK1 and NK3 receptors, (e) antagonists of NK1 receptors, and (f) antagonists of NK2 to treat symptoms and disorders associated with a production and/or secretion of androgen. One aspect of the invention relates to the use of antagonists to suppress production/secretion of androgens in mammals suffering from an androgen-dependent disease, such as benign prostatic hyperplasia and prostatic carcinoma.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: May 27, 2003
    Assignee: Schering Corporation
    Inventors: Michael W. Leach, Mark R. Berardi, Elmer J. Mirro, Dineshwar Sinha, Jonathan A. Pachter, Mark E. Cartwright, Gregory A. Reichard
  • Use of neurokinin receptor antagonists to treat androgen-dependent diseases
    Publication number: 20030092602
    Abstract: Use of an antagonist selected from the group consisting of: (a) antagonists of neurokinin-1 (NK1), neurokinin-2 (NK2) and neurokinin-3 (NK3) receptors, (b) antagonists of NK1 and NK2 receptors, (c) antagonists of NK2 and NK3 receptors, (d) antagonists of NK1 and NK3 receptors, (e) antagonists of NK1 receptors, and (f) antagonists of NK2 to treat symptoms and disorders associated with a production and/or secretion of androgen. One aspect of the invention relates to the use of antagonists to suppress production/secretion of androgens in mammals suffering from an androgen-dependent disease, such as benign prostatic hyperplasia and prostatic carcinoma.
    Type: Application
    Filed: May 7, 2002
    Publication date: May 15, 2003
    Applicant: Schering Corporation
    Inventors: Michael W. Leach, Mark R. Berardi, Elmer J. Mirro, Dineshwar Sinha, Jonathan A. Pachter, Mark E. Cartwright, Gregory A. Reichard